Thomson W H, Harding L K
Department of Nuclear Medicine, City Hospital NHS Trust, Birmingham, UK.
Nucl Med Commun. 1995 Nov;16(11):879-92. doi: 10.1097/00006231-199511000-00002.
This paper reviews the published data relating to the radiation hazards associated with nuclear medicine outpatients. It is discussed both in the context of the current UK advice as well as potential guidelines following the recommendations in ICRP 60. For diagnostic studies there is little need for restrictions. The main exceptions are for a prolonged journey home by public transport with high levels of 99Tcm and for the situation of an outpatient given 111In who has to look after a fretful infant. The main problem occurs following the administration of 131I therapy for thyrotoxicosis. The principal hazards are associated with external exposure; radiation doses from ingestion due to contamination are small. Restrictions should only be necessary for administered activities greater than 400 MBq (e.g. public transport, return to work, sleeping with partner). With such restrictions it is considered that 131I therapy for thyrotoxicosis can continue to be given on an outpatient basis.
本文回顾了已发表的与核医学门诊患者相关的辐射危害数据。文中结合英国当前的建议以及遵循国际放射防护委员会(ICRP)第60号建议的潜在指导方针进行了讨论。对于诊断性检查,几乎无需限制。主要的例外情况是,携带高活度的99锝通过公共交通长途回家,以及接受了铟-111的门诊患者需要照顾烦躁不安的婴儿。主要问题出现在对甲状腺毒症进行碘-131治疗之后。主要危害与外照射有关;因污染导致摄入的辐射剂量较小。仅当给药活度大于400兆贝可(例如乘坐公共交通、重返工作岗位、与伴侣同睡)时才需要限制。有了这些限制,认为对甲状腺毒症的碘-131治疗仍可在门诊进行。